Literature DB >> 21544032

Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients.

Jaewook Yang1, Ian I Hutchinson, Tariq Shah, David I Min.   

Abstract

BACKGROUND: New-onset diabetes after transplantation (NODAT) is one of the major complications after transplantation and is associated with reduced overall patient and graft survival. The objective of this study was to determine the genetic and clinical risk factors for NODAT in Hispanic kidney transplant recipients.
METHODS: Hispanic kidney allograft recipients without evidence of preexisting diabetes who developed NODAT (n=133) were studied using Hispanic kidney transplant recipients with no evidence of diabetes as a control group (n=170). NODAT was defined as fasting glucose levels ≥126 mg/dL on two or more occasions or patients taking any insulin or oral hypoglycemic agents 1 month or later after kidney transplantation. Fourteen alleles in nine genes were genotyped and other patients' clinical data with genotype data were analyzed by logistic regression.
RESULTS: Among 14 alleles, hepatocyte nuclear factor 4 alpha (HNF4A) AA (rs2144908, odds ratio [OR]=1.96, confidence interval [CI]=1.08-3.50, P=0.010), HNF4A TT (rs1884614, OR=2.44, CI=1.42-4.48, P=0.002), and insulin receptor substrate 1 AA+AG (rs1801278, OR=2.71, CI=1.16-6.89, P=0.021) remained significant after logistic regression. Among the clinical factors, average age (OR=1.01, CI=1.00-1.08, P=0.048), sirolimus (OR=5.36, CI=3.02-10.4, P=0.001), deceased donor (OR=1.96, CI=1.16-2.94, P=0.015), and acute rejection (OR=2.92, CI=1.31-5.77, P=0.009) remained significant after logistic regression.
CONCLUSION: This study indicates that polymorphism of two alleles of HNF-4A gene (rs2144908 and rs1884614) and insulin receptor substrate 1 (rs1801278) are significantly associated with NODAT in kidney transplant patients with Hispanic ethnicity. In the case of clinical factors, older age (>50 year), deceased donor type, acute rejection, and sirolimus use are associated with NODAT in Hispanic kidney transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544032     DOI: 10.1097/TP.0b013e31821620f9

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  18 in total

1.  Genetics of new-onset diabetes after transplantation.

Authors:  Jennifer A McCaughan; Amy Jayne McKnight; Alexander P Maxwell
Journal:  J Am Soc Nephrol       Date:  2013-12-05       Impact factor: 10.121

Review 2.  The genetics of kidney transplantation.

Authors:  Nicolas Pallet; Eric Thervet
Journal:  Hum Genet       Date:  2011-09-16       Impact factor: 4.132

3.  Association between E23K variant in KCNJ11 gene and new-onset diabetes after liver transplantation.

Authors:  Zahra Parvizi; Negar Azarpira; Leila Kohan; Masumeh Darai; Kourosh Kazemi; Mohamad Mehdi Parvizi
Journal:  Mol Biol Rep       Date:  2014-07-05       Impact factor: 2.316

Review 4.  Pharmacogenetics of posttransplant diabetes mellitus.

Authors:  P Lancia; T Adam de Beaumais; E Jacqz-Aigrain
Journal:  Pharmacogenomics J       Date:  2017-03-28       Impact factor: 3.550

Review 5.  Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.

Authors:  Vijay Shivaswamy; Brian Boerner; Jennifer Larsen
Journal:  Endocr Rev       Date:  2015-12-09       Impact factor: 19.871

Review 6.  The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.

Authors:  Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

Review 7.  Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms.

Authors:  Adam D Barlow; Michael L Nicholson; Terry P Herbert
Journal:  Diabetes       Date:  2013-08       Impact factor: 9.461

8.  New-onset diabetes after renal transplantation: risk assessment and management.

Authors:  Lidia Ghisdal; Steven Van Laecke; Marc J Abramowicz; Raymond Vanholder; Daniel Abramowicz
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

9.  Evaluation of Angiotensinogen M235T and T174M Polymorphisms, Demographic and Clinical Factors in New-Onset Diabetes after Liver Transplantation in Iranian Patients.

Authors:  S Mottaghi; N Azarpira; A Dehshahri; B Khalvati; S Namazi
Journal:  Int J Organ Transplant Med       Date:  2019

10.  Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus.

Authors:  Mateusz Kurzawski; Krzysztof Dziewanowski; Joanna Łapczuk; Anna Wajda; Marek Droździk
Journal:  Eur J Clin Pharmacol       Date:  2012-05-09       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.